SCHEMBL13566211

SCHEMBL13566211

CC(=O)OCC1OC(C(C)(C)C)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.57
THRB P10828 1/20 0.57
HSD17B10 Q99714 1/20 0.57
TSHR P16473 2/20 0.56
NR3C1 P04150 1/20 0.56
FYN P06241 1/20 0.56
ADRA2A P08913 1/20 0.56
ADORA3 P0DMS8 1/20 0.56
ADRA2B P18089 1/20 0.56
DRD4 P21917 1/20 0.56
DRD3 P35462 1/20 0.56
CA2 P00918 10/20 0.55
CA12 O43570 9/20 0.55
CA1 P00915 9/20 0.55
CA9 Q16790 6/20 0.55
PKM P14618 1/20 0.50
PTPN1 P18031 1/20 0.50
CA4 P22748 5/20 0.48
CA5A P35218 5/20 0.48
CA7 P43166 5/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23590718 1.00 CYP2D6 (0.57) CYP2D6THRBHSD17B10TSHRNR3C1
SCHEMBL23590717 1.00 CYP2D6 (0.57) CYP2D6THRBHSD17B10TSHRNR3C1
SCHEMBL21021361 1.00 CYP2D6 (0.57) CYP2D6THRBHSD17B10TSHRNR3C1
SCHEMBL10147769 0.98 THRB (0.55) CYP2D6THRBHSD17B10TSHRNR3C1
SCHEMBL10147765 0.91 THRB (0.49) CYP2D6THRBHSD17B10TSHRNR3C1
SCHEMBL10147759 0.91 THRB (0.49) CYP2D6THRBHSD17B10TSHRNR3C1
SCHEMBL10147743 0.91 THRB (0.48) CYP2D6THRBHSD17B10TSHRNR3C1
SCHEMBL14003596 0.88 CYP2D6 (0.45) CYP2D6THRBHSD17B10TSHRNR3C1
SCHEMBL19782347 0.87 CYP2D6 (0.59) CYP2D6THRBHSD17B10TSHRNR3C1
SCHEMBL12113494 0.87 CYP2D6 (0.47) CYP2D6THRBHSD17B10TSHRNR3C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230293701-A1 LIGAND COMPOUNDS, CONJUGATES, AND APPLICATIONS THEREOF ARGORNA PHARMACEUTICALS CO., LTD. (CN) 2023-09-21 US disclosed
US-20220041641-A1 QUATERNARY AMMONIUM SALTS AS INHIBITORS OF TRIMETHYLAMINE PRODUCTION SENDA BIOSCIENCES INC (US) 2022-02-10 US disclosed
US-20200369703-A1 Modified oligonucleotides and compound that can be used for synthesizing same GUANGZHOU RIBOBIO CO LTD (CN) 2020-11-26 US disclosed
EP-3564239-A1 ARYL HYDROCARBON RECEPTOR MODULATOR Shenzhen Immunova Pharmaceutical Co., Ltd. (CN) 2019-11-06 EP disclosed
US-9120814-B2 Compounds with embedded benzopyran motif for core structures and preparation method thereof SNU R&DB FOUNDATION (KR) 2015-09-01 US disclosed
US-20090326015-A1 COMPOUNDS WITH EMBEDDED BENZOPYRAN MOTIF FOR CORE STRUCTURES AND PREPARATION METHOD THEREOF SNU R&DB FOUNDATION (KR) 2009-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220041641-A1 QUATERNARY AMMONIUM SALTS AS INHIBITORS OF TRIMETHYLAMINE PRODUCTION SLC10A2, SLC10A1, BCAT2 CYP2D6 2975/4885THRB 1472/4885HSD17B10 2003/4885
US-20090326015-A1 COMPOUNDS WITH EMBEDDED BENZOPYRAN MOTIF FOR CORE STRUCTURES AND PREPARATION METHOD THEREOF BCR, HCCS, YBX3 CYP2D6 287/4885THRB 4798/4885HSD17B10 3181/4885
US-20200369703-A1 Modified oligonucleotides and compound that can be used for synthesizing same POLRMT, RNASE1, ADAR CYP2D6 3340/4885THRB 4067/4885HSD17B10 2906/4885
US-20230293701-A1 LIGAND COMPOUNDS, CONJUGATES, AND APPLICATIONS THEREOF ASGR1, HAVCR2, SLC10A1 CYP2D6 1274/4885THRB 1331/4885HSD17B10 2165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.